The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share.

Novo Nordisk’s stock closed lower on Monday as the weight-loss-drug giant failed to reassure investors about its strategy going ahead. At an investor event on Monday, Novo set out its 2030 ambitions, ...

On Monday, the Danish pharma giant Novo Nordisk A/S (NVO), native ticker NOVO-B.CO, marketer and seller of the obesity/weight loss and type 2 diabetes ("T2D") medications Wegovy and Ozempic, derived ...

The key sentence in the company's announcement about its name change is this one: "As part of this, we will embrace the shorthand 'Novo' as our day-to-day name, while Novo Nordisk A/S remains our ...

Novo set out ambitions to launch more than five potential multi-blockbuster drugs by 2030 on Monday, but shares fell 8%. Analysts said the update offered little new to restore confidence after the ...

Novo Nordisk NOVO.B2.14%increase; up pointing triangle Chief Executive Mike Doustdar, who took over in 2025 promising to find a sustainable growth path, said the company will launch several new ...

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. The deal announced on Thursday gives ...

Alongside a new consumer-focused avenue, Novo's CEO tried to rev up investors by promising to “launch at least five multi-blockbusters by 2030.” (Novo) Novo CEO Mike Doustdar faced a tough crowd as ...

I was bearish on Novo Nordisk A/S in my last coverage before another 20% drop, and the capital markets day still did not win me over. NVO grew sales at a 17% CAGR from 2019 to 2025. Now it is ...

Novo Nordisk NOVO.B-0.50%decrease; down pointing triangle, the Danish drugmaker behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, is partnering with Anthropic to use artificial ...